|
|
| Projects In Knowledge is pleased to present The Advanced Certificate Program: Breast Cancer Management. |
| Featuring the very latest state-of-the-science information about breast cancer diagnosis, breast cancer treatment, and breast cancer disease management, this free online curriculum offers CME, CE, and CPE credit to oncologists and other clinicians who care for patients with breast cancer. |
| The curriculum courses are updated continuously throughout the year. |
| The Advanced Certificate Program: Breast Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible. |
|
|
Co-Chairs: |
|
Harold J. Burstein, MD, PhD
Associate Professor of
Medicine
Dana-Farber Cancer
Institute
Harvard Medical School
Boston, Massachusetts
|
|
|
The robust, 12-month, clinically focused, CME/CE curriculum has been designed to provide in-depth coverage of
- Breast Cancer Pathophysiology
- Cytokines
- Hormones
- Growth factors
- Oncogenes
- Mutation
- Dysregulation of cell signaling
- Vascular endothelial growth factors (VEGF)
- Epidermal growth factors (EGF)
- Nuclear transcription factors (NTF)
- Platelet derived growth factor (PDGF)
- Tyrosine kinase (TK)
- Mammalian target of repamycin (mTOR)
- Apoptosis
- Cell proliferation
- Early- and late-stage breast cancer
- Premenopausal and postmenopausal
- Metastatic breast cancer
- Tumor node metastasis (TNM)
- Estrogen-receptor genes in metastases to bone
- Risk factors and genetics
- Molecular screening
- Biomarkers from DNA, RNA, and protein
- Genetic mutations
- Biologic subsets as predictors of response
- Evidence-based treatment guidelines
- Monoclonal antibodies and tyrosine kinase inhibitors (TKI)
- Cytotoxic chemotherapy
- Third line for metastatic breast cancer
- Targeted agents-systemic therapies
- Current and emerging research data
- HER2+ and HER2-
- Antiangiogenic
- Bevacizumab
- Cetuximab
- Erlotinib
- Imatinib
- Endocrine/hormone therapy
- Hormone agonists as adjuvant treatment
- Premenopausal patients with hormone-receptor-positive breast cancer
- Endocrine therapy
- Postmenopausal patients with estrogen-receptor-positive breast cancer
- Use in advanced breast cancer
- Neoadjuvant therapy
- Dose-dense therapy
- Preoperatively
|
Learning Objectives:
- Assess risk factors, genetics, and biologic subsets as predictors of response to determine which breast cancer patients are likely to benefit from specific therapies to improve their outcomes.
- Apply evidence-based guidelines to formulate treatment strategies for patients with early- and late-stage breast cancer.
- Utilizing knowledge of their efficacy and safety, evaluate the appropriate use of chemotherapeutic and targeted agents in treatment strategies that improve outcomes in breast cancer patients.
- Integrate targeted and novel therapies into more successful treatment regimens for breast cancer patients by assessing the efficacy and safety of these agents.
|
|
| Treatment Strategies Discussed |
- Early stage breast cancer management
- Chemotherapy
- Endocrine/hormone therapy
- Targeted therapy
- Metastatic breast cancer management
- Chemotherapy
- Hormone therapy
- Targeted therapies
- Anti-HER2 agents
- Antiangiogenic agents
- Bone metastasis management
- Neoadjuvant therapy
|
| Featured Presentations |
- Hereditary breast cancer
- Adjuvant treatment for premenopausal women
- Hormone-receptor-positive breast cancer
- Primary endocrine therapy
- Estrogen-receptor-positive breast cancer
- Third line chemotherapy in metastatic breast cancer
- Biomolecular predictors
- Adjuvant systemic therapy in early stage breast cancer
- Estrogen-responsive genes in metastases to the bone
- Cancer risk assessment with biomarkers
- Postoperative treatment with targeted therapies for patients with HER2+ & HER2-
- Dose-dense adjuvant therapy
- Hormonal therapy for advanced breast cancer
- Neoadjuvant systemic therapy
- Molecular screening for breast cancer
- 21-gene recurrence score prognostic assay
|
|
Breast Cancer News powered by
 |
|
|
|
|
|
|
About the Program
